Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galapagos ADR Representing Ord Shs GLPG

Healthcare Biotechnology
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of... see more

Recent & Breaking News (NDAQ:GLPG)

Galapagos reports on historic first quarter 2019

GlobeNewswire April 25, 2019

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

GlobeNewswire April 23, 2019

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS

GlobeNewswire March 28, 2019

Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)

Business Wire March 28, 2019

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY

GlobeNewswire March 28, 2019

Firmly on our way to becoming a fully integrated biopharma company

GlobeNewswire February 21, 2019

Evotec And Galapagos Enter Into Collaboration In The Field Of Fibrosis

Accesswire February 7, 2019

Sands Capital reports 5.7% holding in Galapagos

GlobeNewswire January 8, 2019

Galapagos starts first Phase 1 trial with Toledo compound

GlobeNewswire January 7, 2019

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

GlobeNewswire January 6, 2019

Fibrocor and Galapagos sign partnership in fibrosis

GlobeNewswire January 4, 2019

Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 21, 2018

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire December 17, 2018

Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire December 6, 2018

Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

GlobeNewswire November 27, 2018

Transparency notification

GlobeNewswire November 26, 2018

Galapagos increases share capital through warrant exercises

GlobeNewswire November 23, 2018

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire October 31, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within ICON, Robert Half International, CenterPoint Energy, Galapagos NV, Canadian Pacific Railway, and Mobile Mini — New Research Emphasizes Economic Growth

GlobeNewswire October 29, 2018

AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program

PR Newswire October 24, 2018